Gilead Sciences (GILD) is a Top-Ranked Momentum Stock: Should You Buy?

Company Overview - Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus (HIV) and has a broad portfolio that includes drugs for liver diseases, hematology/oncology diseases, and inflammation/respiratory diseases [12] - The company's flagship treatment, Biktarvy, is driving growth within its strong HIV franchise, which generated total sales of $18.2 billion in 2023, reflecting a 6% year-over-year increase [12] Investment Potential - Gilead Sciences holds a Zacks Rank of 3 (Hold) and has a VGM Score of A, indicating solid performance metrics [13] - The company has a Momentum Style Score of A, with shares appreciating by 11.8% over the past four weeks [13] - Six analysts have revised their earnings estimates upwards for fiscal 2025, with the Zacks Consensus Estimate increasing by$ 0.09 to $7.64 per share, and Gilead boasts an average earnings surprise of 19.5% [13] Conclusion - With a strong Zacks Rank and top-tier Momentum and VGM Style Scores, Gilead Sciences is positioned as a noteworthy option for investors [14]